Abstract
Bone marrow transplantation is now in frequent use for the treatment of a number of hematologic diseases, including severe immune deficiencies, aplastic anemias, and acute and chronic leukemias. In allogeneic transplantation, a problem remains with graft versus host disease-producing immunocompetent cells which contaminate the marrow. In autologous transplantation for treatment of the leukemias, residual leukemic cells may result in the return of unwanted cells to the recipient. Thus, an objective for both autologous and allogeneic marrow transplantation has become the removal of these unwanted cells prior to infusion into the recipient.
University of Minnesota Hospitals and Clinics, 420 Delaware Street S.E., Minneapolis, Minnesota 55455, USA
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Filipovich AH, Ramsay NKC, Warkentin P, McGlave PB, Goldstein G, Kersey JH (1982) Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone marrow transplantation. Lancet 1 /8284: 1266–1269
LeBien TW, Ash RC, Zanjani ED, Kersey JH (1983) In vitro destruction of leukemic cells using a cocktail of monoclonal antibodies. In: Neth R (ed) Modern trends in human leukemia V. Springer, Berlin Heidelberg New York, pp 112–115
Vallera DA, Ash RC, Zanjani ED, Kersey JH, LeBien TW, Beverly PCL, Neville DM Jr, Youle RJ (1983) Anti-T-cell reagents for human bone marrow transplantation: ricin linked to three monoclonal antibodies. Science 222: 512–515
Youle RJ, Neville DM Jr (1980) Anti-thy 1.2 monoclonal antibody linked to ricin is a potent cell-type-specific toxin. Proc Natl Acad Sei USA 77: 5483–5486
U.S. Patent No 4,539, 457, Anti-thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant. Neville DM Jr, Youle RJ U.S. Patent No 4,440,747, Monoclonal antibody- ricin as a treatment of animal graft versus host disease. Neville DM Jr, Youle RJ
Neville DM Jr, Youle RJ (1982) Monoclonal antibody-ricin or ricin A chain hybrids: kinetic analysis of cell killing for tumor therapy. Immunol Rev 62: 135
Rodt HV, Thierfelder S, Eulitz M (1972) Suppression of acute secondary disease by heterologous anti-brain serum. Blut 25: 385–389
Vallera DA, Soderling CCB, Carlson GJ, Kersey JH (1981) Bone marrow transplantation across major histocompatibility barriers in mice: the effect of elimination of T cells from donor grafts by treatment with monoclonal thy 1.2 plus complement or antibody alone. Transplantation 31: 218–222
Vallera DA, Youle RJ, Neville DM Jr, Kersey JH (1982) Bone marrow transplantation across major histocompatibility barriers V. Protection of mice from lethal GVHD by pretreatment of donor cells with monoclonal anti-thy 1.2 coupled to the toxin lectin ricin. J Exp Med 155: 949–954
Youle RJ, Neville DM Jr (1979) Receptormediated transport of the hybrid protein ricin-diphtheria toxin fragment A with subsequent ADP-ribosylation of intracellular elongation factor II. J Biol Chem 24: 11089
Youle RJ, Murray JJ, Neville DM Jr (1979) Ricin linked to monophosphopentamannose bind to fibroblasts lysozomes hydrolase receptors resulting in a cell-type specific toxin. Proc Natl Acad Sei USA 76: 5559
LeBien TW, Kersey JH (1980) A monoclonal antibody (TA-1) reactive with human T lymphocytes and monocytes. J Immunol 125: 2208–2214
LeBien TW, Bradley JG, Koller B (1983) Preliminary structural characterization of the leukocyte cell surface molecule recognized by monoclonal antibody TA-1. J Immunol 130: 1833–1836
Beverley PCL, Callard RE (1981) Distinctive functional characteristics of human T lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody. Eur J Immunol 11: 329
Royston I, Majda A, Baird SM, Meserve BL, Griffiths JC (1979) Monoclonal antibody specific for human T lymphocyte-identification of normal and malignant T-cells. Blood 54: 1069
Filipovich AH, Vallera DA, Youle RJ, Quinones RA, Neville DM Jr, Kersey JH (1984) Ex vivo treatment of donor bone marrow with anti-T-cell immunotoxins for the prevention of graft versus host disease. Lancet 1: 469–471
Stong RC, Youle RJ, Vallera DA (1984) Elimination of clonogenic T-leukemic cells from human bone marrow using anti-Mr 65 000 protein immunotoxins. Cancer Res 4: 3000–3006
Korsmeyer SJ, Arnold A, Bakhshi A, Ravetch JV, Siebenlist U, Hieter PA, Sharrow SO, LeBien TW, Kersey JH, Poplack DG, Leder P, Waldmann TA (1983) Immunoglobulin gene rearrangement and cell surface antigen expression in acute lympho-cytic leukemias of T cell and B cell precursor origins. J Clin Invest 71: 301–313
Abramson CS, Kersey JH, LeBien TW (1981) A monoclonal antibody (BA-1) reactive with cells of human B lymphocyte lineage. J Immunol 126: 83–88
Kersey JH, LeBien TW, Abramson CS, Newman R, Sutherland R, Greaves M (1981) p24: a human leukemia-associated and lymphohemopoietic progenitor cell surface structure identified with monoclonal antibody. J Exp Med 153: 726–731
LeBien TW, Boue DR, Bradley JG, Kersey JH (1982) Antibody affinity may influence antigenic modulation of the common acute lymphoblastic antigen in vitro. J Immunol 129: 2287–2292
LeBien TW, Stepan DE, Bartholomew RM, Stong RC, Anderson JM (1985) Utilization of a colony assay to assess the variables influencing elimination of leukemic cells from human bone marrow with monoclonal antibodies and complement. Blood (in press)
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Kersey, J.H. et al. (1985). Monoclonal Antibodies and Immunotoxins in Bone Marrow Transplantation: Purging Marrow of ALL or GVHD Cells with Preservation of Stem Cells. In: Neth, R., Gallo, R.C., Greaves, M.F., Janka, G. (eds) Modern Trends in Human Leukemia VI New Results in Clinical and Biological Research Including Pediatric Oncology. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 29. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-70385-0_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-70385-0_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-15329-0
Online ISBN: 978-3-642-70385-0
eBook Packages: Springer Book Archive